Back to Journals » Blood and Lymphatic Cancer: Targets and Therapy
Blood and Lymphatic Cancer: Targets and Therapy
ISSN: 1179-9889
- View all (96)
- Volume 13, 2023 (2)
- Volume 12, 2022 (12)
- Volume 11, 2021 (6)
- Volume 10, 2020 (2)
- Volume 9, 2019 (7)
- Volume 8, 2018 (7)
- Volume 7, 2017 (8)
- Volume 6, 2016 (5)
- Volume 5, 2015 (11)
- Volume 4, 2014 (13)
- Volume 3, 2013 (6)
- Volume 2, 2012 (12)
- Volume 1, 2011 (5)
Journal Articles:
- 96 records -
Human Immunodeficiency Virus Related Non-Hodgkin’s Lymphoma
Gessese T, Asrie F, Mulatie Z
Blood and Lymphatic Cancer: Targets and Therapy 2023, 13:13-24
Published Date: 29 May 2023
PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise
Bou Zeid N, Yazbeck V
Blood and Lymphatic Cancer: Targets and Therapy 2023, 13:1-12
Published Date: 8 March 2023
FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation
Blackmon A, Aldoss I, Ball BJ
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:137-147
Published Date: 6 September 2022

CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges
Rendo MJ, Joseph JJ, Phan LM, DeStefano CB
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:119-136
Published Date: 29 August 2022
Differential Diagnosis of Waldenström’s Macroglobulinemia and Early Management: Perspectives from Clinical Practice
Cingam S, Sidana S
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:107-117
Published Date: 18 August 2022

A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?
Chung C
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:99-106
Published Date: 4 August 2022

Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance
St-Pierre F, Ma S
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:81-98
Published Date: 22 July 2022

Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy
Juluri KR, Siu C, Cassaday RD
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:55-79
Published Date: 30 May 2022

Intravascular Large B Cell Lymphoma with CNS Involvement Successfully Treated with High-Dose Methotrexate and High-Dose Ara-C Based CNS-Directed Chemoimmunotherapy Alternating with Anthracycline Based Chemoimmunotherapy
Wang J, Alhaj Moustafa M, Kuhlman JJ, Seegobin K, Jiang L, Gupta V, Tun HW
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:47-54
Published Date: 25 May 2022

HIV/AIDS Associated Lymphoma: Review
Berhan A, Bayleyegn B, Getaneh Z
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:31-45
Published Date: 29 April 2022

Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma
Kuhlman JJ, Alhaj Moustafa M, Jiang L, Wang J, Gupta V, Tun HW
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:23-29
Published Date: 14 April 2022

Neuropsychiatric Manifestations of Lymphoma-Associated Cerebral Glucose Hypometabolism Can Be Reversed by Intensive Glucose Supplementation
Kase AM, Bullock C, Parrondo R, Alhaj Moustafa M, Iqbal M, Li KD, Parent EE, Tun H
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:17-21
Published Date: 23 March 2022

Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia
Hein K, Short N, Jabbour E, Yilmaz M
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:7-16
Published Date: 19 March 2022

How I Manage Patients with Chronic Myeloid Leukemia (CML): Perspectives from Clinical Practice
Guru Murthy GS
Blood and Lymphatic Cancer: Targets and Therapy 2022, 12:1-6
Published Date: 19 March 2022


Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission
Seegobin K, Alhaj Moustafa M, Jiang L, Tun HW
Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:67-72
Published Date: 22 September 2021

Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
Pongas G, Cheson B
Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:55-66
Published Date: 30 July 2021
Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence
Stemer G, Rowe JM, Ofran Y
Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:41-54
Published Date: 22 June 2021

Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review
Bender C, Maese L, Carter-Febres M, Verma A
Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:25-40
Published Date: 19 April 2021

BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma
Gupta VA, Ackley J, Kaufman JL, Boise LH
Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:11-24
Published Date: 12 March 2021
The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia – A Single Center Retrospective Study
Liu Q, Major B, Le-Rademacher J, Al-Kali AA, Alkhateeb H, Begna K, Elliott MA, Gangat N, Hogan WJ, Hook CC, Kaufmann SH, Pardanani A, Patnaik MS, Tefferi A, Wolanskyj-Spinner AP, Wei W, Litzow MR
Blood and Lymphatic Cancer: Targets and Therapy 2021, 11:1-9
Published Date: 22 January 2021

Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy
Sigmund AM, Sahasrabudhe KD, Bhatnagar B
Blood and Lymphatic Cancer: Targets and Therapy 2020, 10:7-20
Published Date: 3 November 2020

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
Ujjani C, Mato A, Hill BT, Allan JN, Lansigan E, Jacobs R, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M
Blood and Lymphatic Cancer: Targets and Therapy 2020, 10:1-5
Published Date: 24 August 2020

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Lai C, Kandahari AM, Ujjani C
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:63-71
Published Date: 9 December 2019

Knockout Of BIRC5 Gene By CRISPR/Cas9 Induces Apoptosis And Inhibits Cell Proliferation In Leukemic Cell Lines, HL60 And KG1
Narimani M, Sharifi M, Jalili A
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:53-61
Published Date: 27 November 2019
Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
Carrà G, Cartellà A, Maffeo B, Morotti A
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:45-52
Published Date: 6 November 2019

Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens
Zhang F, Li L, Zhang L, Li X, Fu X, Wang X, Wu J, Sun Z, Kong F, Ren L, Zhang M
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:33-43
Published Date: 19 August 2019

IDH1-mutated relapsed or refractory AML: current challenges and future prospects
Megías-Vericat JE, Ballesta-López O, Barragán E, Montesinos P
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:19-32
Published Date: 27 June 2019

The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
Schieber M, Ma S
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:9-17
Published Date: 12 March 2019

Strategies for minimal residual disease detection: current perspectives
Andreani G, Cilloni D
Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:1-8
Published Date: 12 February 2019

Plasmablastic lymphoma: current perspectives
Lopez A, Abrisqueta P
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:63-70
Published Date: 4 October 2018

Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia
Hefazi M, Litzow MR
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:47-61
Published Date: 25 September 2018

Current understanding of the role and regulation of miRNAs in Burkitt lymphoma
Videtta AD, Malagnino V, De Falco G
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:33-45
Published Date: 11 May 2018

Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
Blum A, Bazou D, O'Gorman P
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:21-31
Published Date: 20 April 2018

Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era
Lapuz C, Enjeti AK, O'Brien PC, Capp AL, Holliday EG, Gupta SA
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:13-20
Published Date: 18 April 2018
Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [Erratum]
Anagnostou T, Litzow MR
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:11-12
Published Date: 11 April 2018

Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives
Anagnostou T, Litzow MR
Blood and Lymphatic Cancer: Targets and Therapy 2018, 8:1-9
Published Date: 22 December 2017

Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects

Trottier AM, Cerquozzi S, Owen CJ
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:85-93
Published Date: 11 December 2017

Impact of obinutuzumab alone and in combination for follicular lymphoma
Sarraf Yazdy M, Cheson BD
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:73-83
Published Date: 19 October 2017

Complications and management of coagulation disorders in leukemia patients
Lad DP, Jain A, Varma S
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:61-72
Published Date: 18 September 2017

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
Bhutani D, Zonder JA
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:53-60
Published Date: 19 July 2017

Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
Karantanos T, Politikos I, Boussiotis VA
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:37-52
Published Date: 9 May 2017

Clinical potential of midostaurin in advanced systemic mastocytosis
Chandesris MO, Damaj G, Lortholary O, Hermine O
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:25-35
Published Date: 3 May 2017

Uptake of lymphoma-derived exosomes by peripheral blood leukocytes
Ferguson Bennit HR, Gonda A, Oppegard LJ, Chi DP, Khan S, Wall NR
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:9-23
Published Date: 28 February 2017

Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
Oncale MB, Maymani H, Nastoupil LJ
Blood and Lymphatic Cancer: Targets and Therapy 2017, 7:1-7
Published Date: 16 February 2017

Waldenström macroglobulinemia: biology, genetics, and therapy
Paludo J, Ansell SM
Blood and Lymphatic Cancer: Targets and Therapy 2016, 6:49-58
Published Date: 26 July 2016

Managing treatment-related peripheral neuropathy in patients with multiple myeloma
Grammatico S, Cesini L, Petrucci MT
Blood and Lymphatic Cancer: Targets and Therapy 2016, 6:37-47
Published Date: 29 June 2016

Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes
Faiman B, Valent J
Blood and Lymphatic Cancer: Targets and Therapy 2016, 6:21-35
Published Date: 24 May 2016

Ruxolitinib: a targeted treatment option for patients with polycythemia vera
Vaddi K, Verstovsek S, Kiladjian JJ
Blood and Lymphatic Cancer: Targets and Therapy 2016, 6:7-19
Published Date: 12 May 2016

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
Madanat YF, Smith MR, Almasan A, Hill BT
Blood and Lymphatic Cancer: Targets and Therapy 2016, 6:1-6
Published Date: 15 March 2016

Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations
Bodiford A, Talbott MS, Reddy NM
Blood and Lymphatic Cancer: Targets and Therapy 2015, 5:109-114
Published Date: 11 September 2015